Get the app
US › Healthcare

Skye Bioscience, Inc. Common Stock (SKYE)

US · Healthcare · Biotechnology

$1.55-2.52%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-10.8M
EPS
$-0.27
EPS estimate
$-0.29

EPS came in at -0.27 against a street estimate of -0.29 — a beat of 6.9%.

Key statistics

Market cap
$6.8M
Forward P/E
0.0
P/B
1.96
Book value
$-0.11
EPS (TTM)
$-10.16
52-week high
$2.25
52-week low
$0.26
50-day MA
$2.38
200-day MA
$5.26
Beta
2.86

Analyst view

Analysts rate Skye Bioscience, Inc. Common Stock a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $68.00.

Shareholding

Insiders
4.24%
Institutions
40.17%

Largest institutional holders

FundStake
5AM Venture Management, LLC27.33%
Versant Venture Management LLC5.67%
Baker Bros Advisors LP4.45%
Vanguard Capital Management, LLC2.16%
Sphera Funds Management Ltd.1.92%
Junked Platinum Investment Management Ltd0.66%
BlackRock Inc0.66%
Geode Capital Management, LLC0.62%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Skye Bioscience, Inc. Common Stock — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.